NCT03398122

Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 248 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC

Detailed description

HCC The is a common malignancy in the world, especially in China. Advanced HCC treatment is difficult and the prognosis is poor, which is still a great challenge and threat to the medical profession. The advent of the molecular targeted drug, Sola, has made the treatment dilemma of advanced HCC a breakthrough, but the efficacy and economic health ratio is far from satisfactory. After Sola, many new molecular targeted drugs were studied, but failed. Although multiple treatment options, but for HCC Patient-recommended treatment programs require systematic treatment and surgery, TACE , local ablation and radiotherapy and other multidisciplinary means of combination, the selection of appropriate patients, appropriate means and timing to achieve individualized treatment. 1\. Aptinib Union TACE can be generated through embolization and angiogenesis by the dual target of vascular suppression;2. TACE induces hypoxia, leading to an increase in the number of hypoxia-inducing factors that increases VEGF and PDGFR , while VEGF the and PDGFR may be important factors that induce tumor recurrence by stimulating tumor angiogenesis.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
PROCEDURE	TACE	epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
DRUG	Apatinib	a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor

Timeline

• Start date: 2017-11-14
• Primary completion: 2018-10-01
• Completion: 2019-04-01
• First posted: 2018-01-12
• Last updated: 2018-01-12

Locations

1 site across 1 country: China